Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study

ABSTRACT Objectives A post hoc analysis of the Teriparatide Once-Weekly Efficacy Research for Glucocorticoid-induced Osteoporosis (TOWER-GO) study was performed to examine the effect of once-weekly administration of 56.5 μg teriparatide on primary prevention of glucocorticoid-induced osteoporosis (GIOP). Methods Of the subjects of the TOWER-GO study, 73 were included. The percentage changes from baseline in lumbar spine bone mineral density (BMD) and bone turnover markers were evaluated over 72 weeks with once-weekly teriparatide and once-weekly alendronate. Results The percentage change of lumbar spine BMD from baseline at 72 weeks was significantly increased in both groups. Bone formation markers were significantly increased by teriparatide administration, although they were slightly decreased by alendronate administration. Bone resorption markers were gradually decreased by teriparatide, whereas alendronate markedly decreased them within 4 weeks. No major safety concerns arose. Conclusions In this primary prevention study of GIOP, comparable increases in BMD were observed between alendronate and once-weekly teriparatide. More desirable changes in bone markers were observed with teriparatide administration. These data suggest that once-weekly teriparatide is effective in primary prevention of GIOP.

Download Full-text

Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1

BMC Musculoskeletal Disorders ◽

10.1186/s12891-021-04930-1 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Jürgen Braun ◽

Bjoern Buehring ◽

Xenofon Baraliakos ◽

Lianne S. Gensler ◽

Brian Porter ◽

...

Keyword(s):

Lumbar Spine ◽

Ankylosing Spondylitis ◽

Femoral Neck ◽

Bone Turnover ◽

Radiographic Progression ◽

Mineral Density ◽

Post Hoc Analysis ◽

Total Hip ◽

Post Hoc ◽

Bone Turnover Biomarkers

Abstract Background Axial spondyloarthritis including ankylosing spondylitis (AS) is characterized by chronic inflammation and new bone formation in the axial skeleton. On the other hand, bone loss, osteoporosis and an increased risk of vertebral fractures is known to frequently occur in AS. In the MEASURE 1 study, the clinically efficacious interleukin-17A inhibitor secukinumab was shown to have limited radiographic progression through 4 years in patients with active AS. Here we present a post hoc analysis to evaluate the effect of secukinumab on bone mineral density (BMD) and bone turnover biomarkers over 2 years in this study. Methods BMD was measured by dual-energy X-ray absorptiometry at the lumbar spine, total hip, and femoral neck. Spinal radiographs performed at baseline and Week 104 were assessed by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) and analyzed in relation to BMD change, considering baseline syndesmophytes. Bone turnover biomarkers were assessed at baseline and at Weeks 52 or 104. Results Among 104 patients included in this analysis, 66% were male, with a mean (SD) age of 40.4 (12.3) years. In postmenopausal women and men ≥50 years of age (T-score), the proportion of patients having normal BMD at baseline and Week 104 were 54.5%/54.5% (lumbar spine), 31.6%/55.6% (total hip), and 42.1%/44.4% (femoral neck). Similarly, at baseline, the proportion of patients with osteopenia/osteoporosis was 31.8%/13.6% (lumbar spine), 57.9%/10.5% (total hip), 42.1%/15.8% (femoral neck), and 36.4%/9.1% (lumbar spine), 44.4%/0% (total hip) and 55.6%/0% (femoral neck) at Week 104, respectively. In premenopausal women and men < 50 years of age (Z-score), the proportion of patients having BMD below the expected range for age at baseline and Week 104 were 25.0%/21.2% (lumbar spine), 11.3%/17.8% (total hip), and 9.9%/8.9% (femoral neck). In relation to mSASSS change scores ≥2 over 2 years, the increase in lumbar spine BMD was not related to radiographic progression and syndesmophyte formation. No significant changes were observed in the bone turnover markers over time. Conclusion The high proportion of AS patients with diminished BMD was confirmed in this study. An increase of BMD in the lumbar spine after 2 years of secukinumab treatment in patients with AS was found that was probably unrelated to radiographic progression. No relevant effects of secukinumab on bone turnover biomarkers were documented. Trial registration MEASURE 1 (post hoc analysis) Clinicaltrials.gov, NCT01358175; Registered, 23 May 2011.

Download Full-text

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

Osteoporosis International ◽

10.1007/s00198-011-1800-1 ◽

2011 ◽

Vol 23 (3) ◽

pp. 1083-1090 ◽

Cited By ~ 14

Author(s):

C. Roux ◽

D. M. Reid ◽

J.-P. Devogelaer ◽

K. Saag ◽

C. S. Lau ◽

...

Keyword(s):

Bone Mineral Density ◽

Lumbar Spine ◽

Zoledronic Acid ◽

Bone Mineral ◽

Spine Bone Mineral Density ◽

Mineral Density ◽

Post Hoc Analysis ◽

Acid Versus ◽

Post Hoc

Download Full-text

Effect of Lovastatin on Primary Prevention of Cardiovascular Events in Mild CKD and Kidney Function Loss: A Post Hoc Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2009.09.020 ◽

2010 ◽

Vol 55 (1) ◽

pp. 42-49 ◽

Cited By ~ 39

Author(s):

Jessica Kendrick ◽

Michael G. Shlipak ◽

Giovanni Targher ◽

Thomas Cook ◽

Joann Lindenfeld ◽

...

Keyword(s):

Primary Prevention ◽

Kidney Function ◽

Air Force ◽

Cardiovascular Events ◽

Coronary Atherosclerosis ◽

Prevention Study ◽

Post Hoc Analysis ◽

Function Loss ◽

Atherosclerosis Prevention ◽

Post Hoc

Download Full-text

No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis

RMD Open ◽

10.1136/rmdopen-2020-001391 ◽

2020 ◽

Vol 6 (3) ◽

pp. e001391

Author(s):

Mary Lucy Marques ◽

Sofia Ramiro ◽

Pedro M Machado ◽

Desirée van der Heijde ◽

Floris A van Gaalen

Keyword(s):

Bone Mineral Density ◽

Lumbar Spine ◽

Bone Mineral ◽

Axial Spondyloarthritis ◽

Mineral Density ◽

Multivariable Analyses ◽

Low Incidence ◽

Post Hoc ◽

Generalised Estimating Equations ◽

Specific Definition

ObjectiveTo investigate if in radiographic axial Spondyloarthritis (r-axSpA) low vertebral bone mineral density (BMD) is associated with development of new syndesmophytes at the same vertebral level.MethodsIn a post-hoc analysis from the ASSERT trial (infliximab vs placebo), dual-energy X-ray absorptiometry was used to measure baseline BMD (g/cm2) of the lumbar spine L1 to L4. Syndesmophyte formation was assessed in the same vertebrae on conventional radiographs defined as an increase in modified Stoke Ankylosing Spondylitis Spine Score from 0 or 1 to 2 or 3 after 2 years. Radiographs were scored by two readers. Generalised estimating equations (GEE) adjusted for within-patient correlation across multiple vertebrae, taking potential confounders into account.ResultsWe analysed 599 vertebrae in 165 r-axSpA patients (78% male, mean (SD) age 38 (10) years, 67% with at least one syndesmophyte anywhere in the spine). In total, 24 to 74 new syndesmophytes developed in 9 (5%) to 30 (18%) patients and 13 (2%) to 39 (7%) vertebrae, if either a syndesmophyte was seen by both or only one of the readers (ie, specific and sensitive definitions) respectively. In multivariable analyses, no association was found between baseline local vertebral BMD and new syndesmophyte formation after 2 years: adjOR (95% CI): 0.56 (0.01, 44.45) (specific definition) and 0.26 (0.03, 2.63) (sensitive definition).ConclusionIn patients with active and established r-axSpA, with an observed low incidence of lumbar spine syndesmophyte formation over 2 years, no relationship was found between baseline BMD and new radiographic syndesmophyte formation at the same vertebra.

Download Full-text